Allergan plc (NYSE:AGN) – Equities research analysts at Jefferies Financial Group issued their FY2019 earnings per share estimates for Allergan in a research note issued on Tuesday, November 5th. Jefferies Financial Group analyst D. Steinberg anticipates that the company will post earnings per share of $16.78 for the year. Jefferies Financial Group also issued estimates for Allergan’s Q4 2019 earnings at $4.44 EPS, FY2020 earnings at $16.89 EPS, FY2021 earnings at $17.50 EPS, FY2022 earnings at $17.72 EPS and FY2023 earnings at $18.40 EPS.

Allergan (NYSE:AGN) last released its quarterly earnings data on Tuesday, November 5th. The company reported $4.25 earnings per share for the quarter, meeting the consensus estimate of $4.25. Allergan had a positive return on equity of 9.08% and a negative net margin of 58.50%. The company had revenue of $4.03 billion for the quarter, compared to analyst estimates of $3.88 billion. During the same period in the prior year, the company posted $4.25 EPS. The company’s revenue was up 2.9% compared to the same quarter last year.

Several other equities research analysts have also weighed in on AGN. TheStreet upgraded Allergan from a “d+” rating to a “c” rating in a research note on Friday, July 12th. ValuEngine lowered Allergan from a “hold” rating to a “sell” rating in a research report on Wednesday, October 30th. Guggenheim lowered Allergan from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 7th. Svb Leerink restated a “market perform” rating and set a $188.00 price target (down from $217.00) on shares of Allergan in a research report on Thursday, July 18th. Finally, Cantor Fitzgerald increased their price target on Allergan from $125.00 to $165.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 7th. Two equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and five have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $175.16.

AGN stock opened at $181.28 on Friday. Allergan has a 1-year low of $114.27 and a 1-year high of $181.45. The firm has a market cap of $58.54 billion, a P/E ratio of 10.86, a P/E/G ratio of 2.11 and a beta of 1.66. The business’s 50 day moving average is $171.62 and its 200-day moving average is $155.71. The company has a current ratio of 1.67, a quick ratio of 0.91 and a debt-to-equity ratio of 0.39.

A number of large investors have recently bought and sold shares of AGN. Prestige Wealth Management Group LLC acquired a new position in Allergan during the 2nd quarter worth $25,000. Old North State Trust LLC lifted its holdings in Allergan by 172.4% during the 3rd quarter. Old North State Trust LLC now owns 158 shares of the company’s stock worth $27,000 after buying an additional 100 shares in the last quarter. Motco acquired a new position in Allergan during the 2nd quarter worth $29,000. HM Payson & Co. acquired a new position in Allergan during the 2nd quarter worth $29,000. Finally, Reilly Financial Advisors LLC lifted its holdings in Allergan by 129.3% during the 3rd quarter. Reilly Financial Advisors LLC now owns 172 shares of the company’s stock worth $29,000 after buying an additional 97 shares in the last quarter. 80.70% of the stock is currently owned by hedge funds and other institutional investors.

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 13th. Investors of record on Wednesday, November 13th will be given a dividend of $0.74 per share. The ex-dividend date is Tuesday, November 12th. This represents a $2.96 dividend on an annualized basis and a yield of 1.63%. Allergan’s dividend payout ratio (DPR) is presently 17.74%.

Allergan Company Profile

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.

Read More: Why is cost of goods sold important?

Earnings History and Estimates for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.